Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986764644> ?p ?o ?g. }
- W1986764644 endingPage "771.e6" @default.
- W1986764644 startingPage "763" @default.
- W1986764644 abstract "ObjectiveMany asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 μg of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma.MethodsPatients (ages 18-55 years, with asthma [≥1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [≥12%], and self-reported active smoking [≥0.5 to ≤2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during treatment. Adverse experiences (AEs) were also evaluated.ResultsThere were 347, 336, and 336 patients randomized to montelukast, fluticasone, and placebo, respectively. The mean percentage of days with asthma control over 6 months of treatment was 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); the difference between montelukast and fluticasone was not significant (P = .14). Patients with a smoking history of ≤11 pack years (the median value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more benefit with montelukast. AEs occurred in similar proportions among treatment groups.ConclusionsIn a population of asthmatic patients actively smoking cigarettes, both 10 mg/d montelukast and 250 μg of fluticasone propionate twice daily significantly increased the mean percentage of days with asthma control compared with placebo. Many asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 μg of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma. Patients (ages 18-55 years, with asthma [≥1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [≥12%], and self-reported active smoking [≥0.5 to ≤2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during treatment. Adverse experiences (AEs) were also evaluated. There were 347, 336, and 336 patients randomized to montelukast, fluticasone, and placebo, respectively. The mean percentage of days with asthma control over 6 months of treatment was 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); the difference between montelukast and fluticasone was not significant (P = .14). Patients with a smoking history of ≤11 pack years (the median value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more benefit with montelukast. AEs occurred in similar proportions among treatment groups. In a population of asthmatic patients actively smoking cigarettes, both 10 mg/d montelukast and 250 μg of fluticasone propionate twice daily significantly increased the mean percentage of days with asthma control compared with placebo." @default.
- W1986764644 created "2016-06-24" @default.
- W1986764644 creator A5007295323 @default.
- W1986764644 creator A5029221959 @default.
- W1986764644 creator A5033876965 @default.
- W1986764644 creator A5036429383 @default.
- W1986764644 creator A5038822245 @default.
- W1986764644 creator A5052171516 @default.
- W1986764644 creator A5052175038 @default.
- W1986764644 creator A5053062014 @default.
- W1986764644 creator A5077477208 @default.
- W1986764644 creator A5084554470 @default.
- W1986764644 date "2013-03-01" @default.
- W1986764644 modified "2023-10-13" @default.
- W1986764644 title "Effect of montelukast for treatment of asthma in cigarette smokers" @default.
- W1986764644 cites W1968660451 @default.
- W1986764644 cites W1976797956 @default.
- W1986764644 cites W1984963077 @default.
- W1986764644 cites W1986142113 @default.
- W1986764644 cites W1996982788 @default.
- W1986764644 cites W2008915155 @default.
- W1986764644 cites W2009621137 @default.
- W1986764644 cites W2017977879 @default.
- W1986764644 cites W2024081693 @default.
- W1986764644 cites W2043299278 @default.
- W1986764644 cites W2058065620 @default.
- W1986764644 cites W2067068144 @default.
- W1986764644 cites W2072413258 @default.
- W1986764644 cites W2073802634 @default.
- W1986764644 cites W2082695270 @default.
- W1986764644 cites W2095591678 @default.
- W1986764644 cites W2099088996 @default.
- W1986764644 cites W2101864423 @default.
- W1986764644 cites W2105045168 @default.
- W1986764644 cites W2113075038 @default.
- W1986764644 cites W2117256477 @default.
- W1986764644 cites W2127923724 @default.
- W1986764644 cites W2128053026 @default.
- W1986764644 cites W2133024000 @default.
- W1986764644 cites W2136199835 @default.
- W1986764644 cites W2141007076 @default.
- W1986764644 cites W2157242620 @default.
- W1986764644 cites W2158491499 @default.
- W1986764644 cites W2163521166 @default.
- W1986764644 cites W2165465489 @default.
- W1986764644 cites W2165829211 @default.
- W1986764644 cites W2313383114 @default.
- W1986764644 cites W2324465394 @default.
- W1986764644 cites W4249212674 @default.
- W1986764644 doi "https://doi.org/10.1016/j.jaci.2012.12.673" @default.
- W1986764644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23380218" @default.
- W1986764644 hasPublicationYear "2013" @default.
- W1986764644 type Work @default.
- W1986764644 sameAs 1986764644 @default.
- W1986764644 citedByCount "56" @default.
- W1986764644 countsByYear W19867646442013 @default.
- W1986764644 countsByYear W19867646442014 @default.
- W1986764644 countsByYear W19867646442015 @default.
- W1986764644 countsByYear W19867646442016 @default.
- W1986764644 countsByYear W19867646442017 @default.
- W1986764644 countsByYear W19867646442018 @default.
- W1986764644 countsByYear W19867646442019 @default.
- W1986764644 countsByYear W19867646442020 @default.
- W1986764644 countsByYear W19867646442021 @default.
- W1986764644 countsByYear W19867646442022 @default.
- W1986764644 countsByYear W19867646442023 @default.
- W1986764644 crossrefType "journal-article" @default.
- W1986764644 hasAuthorship W1986764644A5007295323 @default.
- W1986764644 hasAuthorship W1986764644A5029221959 @default.
- W1986764644 hasAuthorship W1986764644A5033876965 @default.
- W1986764644 hasAuthorship W1986764644A5036429383 @default.
- W1986764644 hasAuthorship W1986764644A5038822245 @default.
- W1986764644 hasAuthorship W1986764644A5052171516 @default.
- W1986764644 hasAuthorship W1986764644A5052175038 @default.
- W1986764644 hasAuthorship W1986764644A5053062014 @default.
- W1986764644 hasAuthorship W1986764644A5077477208 @default.
- W1986764644 hasAuthorship W1986764644A5084554470 @default.
- W1986764644 hasBestOaLocation W19867646441 @default.
- W1986764644 hasConcept C126322002 @default.
- W1986764644 hasConcept C142724271 @default.
- W1986764644 hasConcept C168563851 @default.
- W1986764644 hasConcept C197934379 @default.
- W1986764644 hasConcept C204787440 @default.
- W1986764644 hasConcept C27081682 @default.
- W1986764644 hasConcept C2776042228 @default.
- W1986764644 hasConcept C2776322731 @default.
- W1986764644 hasConcept C2779028295 @default.
- W1986764644 hasConcept C2781212218 @default.
- W1986764644 hasConcept C42219234 @default.
- W1986764644 hasConcept C71924100 @default.
- W1986764644 hasConceptScore W1986764644C126322002 @default.
- W1986764644 hasConceptScore W1986764644C142724271 @default.
- W1986764644 hasConceptScore W1986764644C168563851 @default.
- W1986764644 hasConceptScore W1986764644C197934379 @default.
- W1986764644 hasConceptScore W1986764644C204787440 @default.
- W1986764644 hasConceptScore W1986764644C27081682 @default.
- W1986764644 hasConceptScore W1986764644C2776042228 @default.
- W1986764644 hasConceptScore W1986764644C2776322731 @default.